OSN’s top news of the week

Here are some of the top stories of the past week on Healio.com/OSN:

 

Retinal alterations noted in preclinical Alzheimers disease

Subjects with preclinical Alzheimer’s disease had a larger foveal avascular zone and decreased inner foveal thickness compared with subjects without preclinical Alzheimer’s disease. Read more.

 

RSA starts pay-it-forward refractive surgery training program

The Refractive Surgery Alliance is creating a new training program for vision correction surgeons that will allow fellows to train at multiple sites. Read more.

 

Apellis begins phase 3 clinical program for geographic atrophy treatment

A two-trial phase 3 clinical program for APL-2 for geographic atrophy has begun with the first patient enrolled in the DERBY trial and the first patient dosed in the OAKS trial, Apellis Pharmaceuticals announced. Read more.

 

FDA to review Eylea for diabetic retinopathy

Data from the phase 3 PANORAMA trial found positive top-line results for Eylea (aflibercept) injection after 6 months in patients with moderately severe to severe nonproliferative diabetic retinopathy without diabetic macular edema. Read more.

 

FDA approves STAARs Visian Toric ICL for myopia with astigmatism

STAAR Surgical’s Visian Toric Implantable Collamer Lens has been approved by the FDA for the correction of myopia with astigmatism. Read more.

Here are some of the top stories of the past week on Healio.com/OSN:

 

Retinal alterations noted in preclinical Alzheimers disease

Subjects with preclinical Alzheimer’s disease had a larger foveal avascular zone and decreased inner foveal thickness compared with subjects without preclinical Alzheimer’s disease. Read more.

 

RSA starts pay-it-forward refractive surgery training program

The Refractive Surgery Alliance is creating a new training program for vision correction surgeons that will allow fellows to train at multiple sites. Read more.

 

Apellis begins phase 3 clinical program for geographic atrophy treatment

A two-trial phase 3 clinical program for APL-2 for geographic atrophy has begun with the first patient enrolled in the DERBY trial and the first patient dosed in the OAKS trial, Apellis Pharmaceuticals announced. Read more.

 

FDA to review Eylea for diabetic retinopathy

Data from the phase 3 PANORAMA trial found positive top-line results for Eylea (aflibercept) injection after 6 months in patients with moderately severe to severe nonproliferative diabetic retinopathy without diabetic macular edema. Read more.

 

FDA approves STAARs Visian Toric ICL for myopia with astigmatism

STAAR Surgical’s Visian Toric Implantable Collamer Lens has been approved by the FDA for the correction of myopia with astigmatism. Read more.